Wells Fargo’s Sarepta Therapeutics SRPT Stock Holding History

Wells Fargo’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-55,000	Closed	-$5.3M	–	7699
2023 Q4	$5.3M	Hold	55,000	–	–	﹤0.01%	2177
2023 Q3	$6.67M	Buy	55,000 +46,100	+518%	+$5.21M	﹤0.01%	1903
2023 Q2	$1.02M	Hold	8,900	–	–	﹤0.01%	3463
2023 Q1	$1.23M	Hold	8,900	–	–	﹤0.01%	3237
2022 Q4	$1.15M	Buy	+8,900	New	+$1.03M	﹤0.01%	3161
2021 Q2	–	Sell	-13,600	Closed	-$1.01M	–	7404
2021 Q1	$1.01M	Sell	13,600 -6,200	-31%	-$572K	﹤0.01%	4237
2020 Q4	$436K	Buy	19,800 +10,700	+118%	+$1.59M	﹤0.01%	4615
2020 Q3	$264K	Buy	+9,100	New	+$1.38M	﹤0.01%	4797
2019 Q3	–	Sell	-3,200	Closed	-$2K	–	6698
2019 Q2	$2K	Buy	+3,200	New	+$389K	﹤0.01%	6181

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo's SRPT Position: Q1 2026 in Review

Wells Fargo reduced its Sarepta Therapeutics (SRPT) stake by 24% in Q1 2026, selling an estimated $784K and leaving 127,200 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #3018.

Wells Fargo first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $113M in Q4 2020. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Wells Fargo held 127,200 shares of Sarepta Therapeutics worth $2.77M as of Q1 2026.
Wells Fargo sold 40,525 Sarepta Therapeutics shares in Q1 2026, an estimated $784K.
Sarepta Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3018 holding.
Wells Fargo first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
Wells Fargo's Sarepta Therapeutics position peaked at $113M in Q4 2020.
340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.